

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 09/931732  
 Filing Date August 16, 2001  
 First Named Inventor Brown et al.  
 Art Unit 1635  
 Examiner Jon Benjamin Ashen  
 Attorney Docket No. GENP.001CI

(Multiple sheets used when necessary)

SHEET 1 OF 2

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
JBA	1	5,872,242	2/1999	Monia et al.	
	2	5,898,031	4/1999	Crooke, Stanley T..	
	3	6,077,833	6/2000	Bennett et al.	
	4	6,107,094	8/2000	Crooke, Stanley T.	
	5	6,197,556	2/1/2001	Ulanovsky et al.	
	6	6,287,772	9/1/2001	Stefano et al.	
	7	6,346,938	2/2002	Pavco et al.	
	8	6,380,368	4/2002	Froehler et al.	
	9	6,391,593	5/1/2002	Weston et al.	
	10	6,451,588	9/1/2002	Egholm et al.	
	11	6,465,193	10/1/2002	Akeson et al.	
	12	6,905,820	6/1/2005	Uhlmann et al.	
	13	09/931732	8/16/2001	Brown et al.	
	14	09/932129	8/16/2001	Brown, Bob D.	
	15	10/142566	5/8/2002	Riley et al.	
	16	10/142666	5/8/2002	Brown et al.	
	17	10/142729	5/8/2005	Brown et al.	
	18	10/375504	2/25/2003	Brown et al.	
	19	10/621009	7/15/2003	Brown, Bob D.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
JBA	20	WO 95/01985	1/19/1995	Gryaznov, Sergei, M.		
	21	WO 97/18312	5/22/1997	Ludwig et al.		
	22	WO 97/26270	7/24/1997	Wincott et al.		
	23	WO 98/58057	12/23/1998	Ludwig et al.		
	24	WO 99/18238	4/15/1999	Riley et al.		
	25	Copy of PCT International Search Report, PCT/US00/09293 in 4 pages	8/8/2000			

Examiner Signature

Date Considered

10/24/05

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	09/931732
	Filing Date	August 16, 2001
	First Named Inventor	Brown et al.
	Art Unit	1635
(Multiple sheets used when necessary)	Examiner	Jon Benjamin Ashen
SHEET 2 OF 2	Attorney Docket No.	GENP.001C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
JBA	26	Copy of PCT International Preliminary Examination Report, PCT/US00/09293 in 6 pages	6/29/2001			
	27	Copy of Supplementary Partial European Search Report, EP 00 92 1855 in 9 pages	9/19/2003			
	28	Copy of PCT International Search Report, PCT/US00/09230 in 5 pages	7/24/2000			
	29	Copy of PCT International Preliminary Examination Report, PCT/US98/20361 in 7 pages	1/20/2000			
	30	Copy of PCT International Search Report, PCT/US98/20361 in 5 pages	2/2/1999			
	31	Copy of Supplementary Partial European Search Report, EP 98 94 8573 in 5 pages	10/15/2004			
	32	Copy of International Search Report, PCT/US93/10103 in 2 pages	7/4/1998			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
JBA	33	Agrawal et al. Antisense therapeutics: Is it as simple as complementary base recognition? Molecular Medicine Today, 2000 Vp: 6:72-81	
	34	Branch, AD. A good antisense molecule is hard to find. TIBS, 1998 Vol. 23:45-50.	
	35	Deb et al. RNA-Dependent Protein Kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. Journal of Immunology, 2001 Vol. 166:6170-6180	
	36	Jen et al. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells, 2000 Vol. 18:307-319	
	37	Kuwabara et al. "Activities of tRNA-embedded dimeric minizymes," Nucleic Acids Symposium Series, no. 37: 307-308 (1997).	
	38	Tidd, Ed D.M.. "Ribonuclease H-Mediated Antisense Effects of Oligonucleotides and Controls for Antisense Experiments," Applied Antisense Oligonucleotide Technology, pp161-171 (1998)	

1835373/072705:sm

Examiner Signature		Date Considered	W/20/05
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.